Opyl is providing consulting services to Paul Rennie's Paradigm Pharmaceuticals.
OPL chairman, Saurabh Jain, discloses the PAR relationship in an 8 minute interview with Niv Gagan, CEO of Peak Asset Management.
Dagan is OPL's second largest shareholder.
He notes in the interview posted on LinkedIn that he'll be joining OPL directors for dinner.
Paradigm is planning an important Phase 3 clinical trial of it's key iPPS compound in osteo-arthritis.
It seems likely that OPL's AI tech will be used in PAR's trial design.
- Forums
- ASX - By Stock
- OPL
- Opyl links with PAR/Paradigm Pharmaceuticals
Opyl links with PAR/Paradigm Pharmaceuticals
Featured News
Add OPL (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.7¢ |
Change
0.003(21.4%) |
Mkt cap ! $2.902M |
Open | High | Low | Value | Volume |
1.7¢ | 1.7¢ | 1.7¢ | $2.784K | 163.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 34500 | 1.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.3¢ | 4000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 34500 | 0.017 |
1 | 2000000 | 0.016 |
2 | 221015 | 0.014 |
1 | 153000 | 0.013 |
1 | 150000 | 0.012 |
Price($) | Vol. | No. |
---|---|---|
0.023 | 4000 | 1 |
0.025 | 40003 | 1 |
0.030 | 500000 | 1 |
0.032 | 105961 | 1 |
0.033 | 233333 | 1 |
Last trade - 13.29pm 17/09/2024 (20 minute delay) ? |
Featured News
OPL (ASX) Chart |